Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R. McKay, Toni K. Choueiri, Xiao X. Wei et al.|Journal of Clinical Oncology|2020Cited by 105
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancerBenjamin L. Maughan, Emmanuel S. Antonarakis, Daniel L. Suzman et al.|Cancer Chemotherapy and Pharmacology|2016Cited by 31